KINOXIS THERAPEUTICS
Kinoxis Therapeutics is an early stage biotechnology company based in Australia that is working to progress the development of a range of novel therapeutic compounds for the treatment of substance use disorders and other CNS conditions. The company has licensed these compounds from the University of Sydney, with the lead candidate demonstrating potent anti-addictive and prosocial effects in a number of different animal models and is progressing through pre-clinical testing.
KINOXIS THERAPEUTICS
Industry:
Biotechnology Therapeutics
Founded:
2017-01-01
Address:
Melbourne, Victoria, Australia
Country:
Australia
Website Url:
http://www.kinoxistherapeutics.com
Total Employee:
1+
Status:
Active
Total Funding:
7.7 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Font API Google Analytics Apple Mobile Web Clips Icon Google Tag Manager WordPress Font Awesome
Similar Organizations
Axcella
Axcella is a biotechnology company that treats diseases using endogenous metabolic modulators.
Cedilla Therapeutics
Cedilla Therapeutics is a biotechnology company that develops targeted small molecules for the treatment of cancer and other diseases.
Remix Therapeutics
Remix Therapeutics is a biotechnology company.
Vesigen Therapeutics
Vesigen Therapeutics is a biotechnology company that develops groundbreaking therapeutic products.
Current Employees Featured
Founder
Investors List
National Institutes of Health
National Institutes of Health investment in Grant - Kinoxis Therapeutics
Uniseed Ventures
Uniseed Ventures investment in Seed Round - Kinoxis Therapeutics
Stoic VC
Stoic VC investment in Seed Round - Kinoxis Therapeutics
Stoic VC
Stoic VC investment in Venture Round - Kinoxis Therapeutics
Uniseed Ventures
Uniseed Ventures investment in Venture Round - Kinoxis Therapeutics
Official Site Inspections
http://www.kinoxistherapeutics.com
- Host name: syn121.syd2.hostyourservices.net
- IP address: 103.27.32.16
- Location: Leumeah Australia
- Latitude: -34.0496
- Longitude: 150.8354
- Timezone: Australia/Sydney
- Postal: 2560
More informations about "Kinoxis Therapeutics"
About Us - Kinoxis Therapeutics
We work with urgency to support the millions of patients and their loved ones who are suffering from social challenges and substance use disorders.See details»
Kinoxis Therapeutics - Crunchbase Company Profile
Kinoxis Therapeutics is a biotechnology company that develops a range of novel therapeutic compounds.See details»
Kinoxis Therapeutics 2025 Company Profile: Valuation, Funding ...
Information on valuation, funding, cap tables, investors, and executives for Kinoxis Therapeutics. Use the PitchBook Platform to explore the full profile.See details»
Kinoxis Therapeutics Pty Ltd - The Org
Kinoxis Therapeutics is a private, Australian-based, clinical stage biotechnology company developing first-in-class therapeutics to address the escalating demand for effective …See details»
Kinoxis Therapeutics - 2025 Company Profile & Team - Tracxn
Jun 25, 2025 Kinoxis Therapeutics - Developer of therapies fort treating CNS disorders. Raised a total funding of $13.4M over 3 rounds from 6 investors.See details»
Kinoxis Therapeutics | VentureRadar
Kinoxis Therapeutics is a clinical-stage biotechnology company focused on developing first-in-class therapeutics for social dysfunction and substance use disorders. By targeting pathways …See details»
Kinoxis Therapeutics | Uniseed
Kinoxis Therapeutics Pty Ltd is a start-up company from the University of Sydney that is developing a novel therapy for addiction. Substance use disorders, including the abuse of …See details»
Kinoxis Therapeutics | Melbourne Startups
Kinoxis Therapeutics is a biotechnology company based in Melbourne, Australia, focused on the development of therapies for substance use disorders and other central nervous system …See details»
Kinoxis Therapeutics - Social Neuroscience Guided Therapeutics
Developing novel therapeutics for social dysfunction and substance use disorders.See details»
Kinoxis Therapeutics Company Insights, Tech Stack, and …
Find useful insights on Kinoxis Therapeutics's company details, tech stack, news alerts, competitors and more. Use 6sense to connect with top decision-makers at Kinoxis Therapeutics.See details»
Kinoxis Therapeutics - VentureRadar
Sun BioPharma USA Private Sun BioPharma is developing small-molecule pharmaceuticals consisting of novel polyamine analogues and metal chelators, and MGI Pharma, a …See details»
Uniseed investee Kinoxis awarded new US grant funding to …
Jun 8, 2023 Learn more at www.kinoxistherapeutics.com. About Uniseed Uniseed (www.uniseed.com) is a venture fund operating at the Universities of Melbourne, Queensland, …See details»
Kinoxis Therapeutics - VentureRadar
Wavecraft Sweden Private A 'world-first' technology platform - precise microwave-controlled heating of chemical reactions in flowing liquids. We focus on solutions to support development …See details»
Kinoxis awarded new US grant funding to support clinical …
Jun 8, 2023 KNX100 is a small molecule in development for the treatment of substance use disorders, including symptoms associated with withdrawal from opioids US$3.6 million …See details»
Pipeline - Kinoxis Therapeutics
Overview of the Kinoxis pipeline: KNX100 and Oxytocin Targeting Compounds.See details»
Sydney spinout lands $273m deal to develop drugs for psychiatric ...
May 5, 2023 Compounds that target oxytocin receptors in the brain are being developed into medicines to treat schizophrenia and other psychiatric disorders in a landmark $273m …See details»
Uniseed Investee Kinoxis Therapeutics partners with Boehringer ...
Melbourne, Australia, 5 May 2023 – Uniseed investee Kinoxis Therapeutics today announced a strategic partnership and licensing agreement with Boehringer Ingelheim for the development …See details»
MEDIA RELEASE - Kinoxis Therapeutics
Kinoxis Therapeutics partners with Boehringer Ingelheim to develop novel treatments for psychiatric patients with social dysfunction symptoms Melbourne, Australia, 5 May 2023 – …See details»
Kinoxis Secures $2.5M CUREator+ Grant to support CARES-X, a …
Dec 23, 2024 Kinoxis Therapeutics is pleased to announce that it has been awarded a $2.5 million grant from the CUREator+ program. The grant will support Kinoxis’ CARES-X Study, a …See details»
Sydney spinout lands $273m deal to develop drugs for psychiatric ...
May 5, 2023 Kinoxis Therapeutics partners with Boehringer Ingelheim to develop novel treatments for psychiatric patients with social dysfunction symptoms Melbourne, Australia, 5 …See details»